apoquel chewable
(oclacitinib chewable tablet)

apoquel
(oclacitinib tablet)



FOR RAPID, POWERFUL ALLERGIC ITCH RELIEF[1-3]

THINK F.A.S.T.

***F**our-hour onset*[1,4] **A**poquel **S**teroid-free **T**reatment*



The only non-steroidal treatment for canine allergic itch demonstrated to start working in 4 hours*[1,4]

- Demonstrated to relieve allergic itch rapidly
- Apoquel worked as fast as steroids in a clinical study[1,5]
- 96% of veterinarians are satisfied with Apoquel's efficacy[6]

*Data for Apoquel Chewable based on a model study for flea allergic dermatitis.

apoquel chewable
(oclacitinib chewable tablet)

apoquel
(oclacitinib tablet)



FOR RAPID, POWERFUL ALLERGIC ITCH RELIEF[1-3]

THINK F.A.S.T.

Apoquel starts to work in 4 hours* AND provides trusted benefits[1,4]

Demonstrated safety profile backed by investigational and independent studies over 10 years[7-9]

- Works differently from steroids – targets specific cytokines that cause itch and inflammation – with minimal impact on the immune system[10,11]
- Safety profile allows for Apoquel administration regardless of vaccine status/schedules – no need to discontinue use
- A long-term compassionate use study concluded that Apoquel was safe and effective for long-term use[7]

The #1 prescribed oral treatment for allergic itch[12]

15 million dogs

- Trusted to treat more than 15 million dogs for over a decade[13†]
- #1 in veterinarian and pet owner satisfaction for oral medications for allergic itch in dogs[6,14]

*Data for Apoquel Chewable based on a model study for flea allergic dermatitis.
†Apoquel tablet launched January 2014, Apoquel Chewable launched October 2023.

apoquel chewable
(oclacitinib chewable tablet)

apoquel
(oclacitinib tablet)



THINK APOQUEL CHEWABLE

The first and only chewable dosing option for canine allergic itch

Like Apoquel tablets, Apoquel Chewable can be taken with or without food*



Canine-approved

- 91.6% of dogs voluntarily accepted Apoquel Chewable twice a day for 7 days[15]

Now available in convenient 100-count blister packs

*No specific studies have been conducted to compare the PK of Apoquel Chewable when administered with or without food. The active ingredient in Apoquel Chewable has been shown to be unaffected by food.

apoquel chewable (oclacitinib chewable tablet) | apoquel (oclacitinib tablet)



Apoquel use includes:

- Short-term treatment of flares
- Long-term maintenance therapy
- Start-and-stop itch control during diagnostic trials



For relief of canine allergic itch

Recommend Apoquel first-line for the fast relief loved by itchy dogs

For helpful resources to support your practice and patients, visit Apoquel.com

APOQUEL AND APOQUEL CHEWABLE INDICATIONS: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL AND APOQUEL CHEWABLE IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines.

See full Prescribing Information at ApoquelTabletAndChewablePI.com

References: 1. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. *Vet Dermatol.* 2014;25(6):512-e86. **2.** Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. *Vet Dermatol.* 2013;24(5):479-e114. **3.** Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (APOQUEL®) in client-owned dogs with atopic dermatitis. *Vet Dermatol.* 2013;24(6):587-e142. **4.** Data on file, Study Report No. A162R-US-21-C32, 2022, Zoetis Inc. **5.** Data on file, Study Report No. A161R-AU-12-096, Zoetis Inc. **6.** Data on file, Apoquel/Cytopoint Vet Tracker Wave 18, 2024, Zoetis Inc. N=744 veterinarians. **7.** Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. *Vet Dermatol.* 2015;26(3):171-179. **8.** Nederveld SM, et al. Safety of the selective JAK1 inhibitor oclacitinib in dogs. *J Vet Pharmacol Ther.* 2025;1-11. doi:10.1111/jvp.13503 **9.** Data on file. A Ten-Year Post-Approval Safety Review for APOQUEL® in the US (May 2013 to August 2023), Zoetis Inc. **10.** Banovic F, Tarigo J, Gordon H, et al. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production. *Vet Dermatol.* 2019;30(1):17-e6. **11.** Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. *J Vet Pharmacol Ther.* 2014;37(4):317-324. **12.** Kynetec - PetTrak, US Pruritus Factored National. May 2025 MAT Canine Pruritus, Total Unique Patients on Apoquel. Zoetis Inc. **13.** Kynetec PetTrak-GAH-284: Unique Patient Count since Launch Custom Report: Apoquel: January 2014 – March 2025. **14.** Data on file, Apoquel/Cytopoint Pet Owner Tracker Wave 13, 2024, Zoetis Inc. N=517 pet owners. **15.** Visser M, Walsh K, King V, et al. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis. *BMC Vet Res.* 2022;18(1):103. doi:10.1186/s12917-022-03210-x

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2025 Zoetis Services LLC. All rights reserved. APQ-01634R2

zoetis